INOV8 R3ta Plus 2

INOV8 R3ta Plus 2 is an advanced hybrid peptide system combining the potent triple-agonist Retatrutide with NAD+ for cellular vitality and L-Carnitine for fat metabolism. This unique formula supports long-term weight management while fueling mitochondrial energy and preserving lean mass.

Each 2.6 mL Pen (240 clicks) contains:

• Retatrutide: 30 mg
• NAD+: 500 mg
• L-Carnitine: 1000 mg

Per Click (≈0.0108 mL):

• Retatrutide ~0.125 mg
• NAD+ ~2.08 mg
• L-Carnitine ~4.17 mg

Directions for Use

• Frequency: Twice weekly injections (approx. every 3–4 days).
• Best Time: Morning or early afternoon → maximizes appetite control, energy, and fat metabolism during the day.
• Method: Subcutaneous injection. Rotate injection sites, use sterile, single-use needles.
• Storage: Refrigerate (2–8 °C), protect from light.

Dosing Schedule:

Week	Monday Dose	Thursday Dose	Total Clicks/Week
1	8 clicks	8 clicks	16 clicks
2	10 clicks	10 clicks	20 clicks
3	12 clicks	12 clicks	24 clicks
4	14 clicks	14 clicks	28 clicks
5	16 clicks	16 clicks	32 clicks
6	18 clicks	18 clicks	36 clicks

Compound Data

Ingredient	Function	Benefits
Retatrutide	Triple-agonist (GLP-1, GIP, Glucagon)	Superior appetite suppression, enhanced fat burning, improved glucose metabolism
NAD+	Central coenzyme in redox and mitochondrial energy	Supports ATP production, DNA repair, anti-aging, improved cellular resilience
L-Carnitine	Shuttles fatty acids into mitochondria	Enhances fat oxidation, improves energy levels, boosts exercise performance

Quality Assurance

• Manufactured in GMP-certified facilities with sterile fill & finish.
• Purity testing: HPLC and MS verification of Retatrutide, NAD+, and L-Carnitine.
• Batch-coded pens with traceability and expiry.
• Supplied with medical-grade sterile needles.
• Cold-chain logistics ensure NAD+ stability and potency.

Safety & Warnings

• For adult use only (18+).
• Not recommended during pregnancy, or in patients with uncontrolled endocrine, liver, or kidney disorders.
• Side effects may include mild nausea or GI upset in early weeks (common with GLP-1s).
• Monitoring advised: blood glucose, lipid profile, liver/kidney markers.
• Use in 12-week cycles with 2–4 week breaks before repeating.

Additional Reading

• NEJM: Retatrutide clinical trials in obesity and metabolic disorders.
• Cell Reports: Role of NAD+ in aging and mitochondrial energy.
• Sports Medicine: Effects of L-Carnitine on exercise recovery and fat metabolism.
• Lancet Diabetes & Endocrinology: Advances in combination incretin therapies.

With R3ta Plus 2, weight loss isn’t the only outcome — it’s about fueling your body, powering your cells, and achieving sustainable vitality.

Buy Now!

 

Disclaimer

All INOV8 Pharma products are intended for laboratory and research purposes only. They are not approved for human consumption, medical use, or therapeutic application. These products are not intended to diagnose, treat, cure, or prevent any disease. Always handle peptides in accordance with proper laboratory safety and research protocols.